Downregulation of nephrin in podocytes leads to development of proteinuria in human and experimental kidney diseases.
Here, we evaluated the exact mode of action of cathepsin L in the development of proteinuria in streptozotocin-induced diabetes.
Recently, animal studies have shown that the urinary excretion of PTGDS may predict the development of proteinuria and renal injury [30].
The development of proteinuria is associated with an earlier gestational age at delivery, lower birth weight, and an increased incidence of small-for-gestational age newborns.
Preeclampsia (the development of proteinuria and hypertension after 20 weeks of gestation) is common; however, there is uncertainty about the natural history of subsequent kidney disease.
Cathepsin L, a lysosomal cysteine protease, can be involved in the development of proteinuria by degradation of proteins that are important for normal podocyte architecture, such as the CD2-associated protein, synaptopodin, and dynamin.
Development of proteinuria and survival were measured.
Furthermore, palosuran increased renal blood flow and delayed the development of proteinuria and renal damage [46].
Development of proteinuria, defined as ≥100 mg/dl on serial testing, and survival in treatment and control cohorts were compared by χ2 analysis using the Yates correction.
In women who had hypertension but no proteinuria at baseline, a diagnosis of preeclampsia required the development of proteinuria or thrombocytopenia.
In order to examine the impact of anti-dsDNA antibodies on development of proteinuria, we analyzed if the presence of anti-dsDNA antibodies correlated with proteinuria.
